Susquehanna International Group
XLO icon

Susquehanna International Group’s Xilio Therapeutics XLO Stock Holding History

Susquehanna International Group’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,507
Closed -$46.9K – 13587
2024
Q4 		$46.9K Buy
+3,507
New +$48.2K ﹤0.01% 11704

Other funds holding XLO

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Susquehanna International Group's XLO Position: Q1 2025 in Review

Susquehanna International Group sold out of Xilio Therapeutics (XLO) in Q1 2025, closing a stake of 3,507 shares — an estimated $46.9K sold.

Susquehanna International Group first reported a position in XLO in Q4 2024 and held it in 1 quarter. The position peaked at $46.9K in Q4 2024. 35 funds tracked by Wall St. Rank hold XLO as of Q1 2025.

  • Susquehanna International Group reported no remaining Xilio Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 3,507 Xilio Therapeutics shares in Q1 2025, an estimated $46.9K.
  • Susquehanna International Group first reported a position in Xilio Therapeutics in Q4 2024 and held it in 1 quarter.
  • Susquehanna International Group's Xilio Therapeutics position peaked at $46.9K in Q4 2024.
  • 35 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.